Surachet Imlimthan

428 total citations
23 papers, 321 citations indexed

About

Surachet Imlimthan is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Materials Chemistry. According to data from OpenAlex, Surachet Imlimthan has authored 23 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 6 papers in Materials Chemistry. Recurrent topics in Surachet Imlimthan's work include Radiopharmaceutical Chemistry and Applications (12 papers), Boron Compounds in Chemistry (5 papers) and Peptidase Inhibition and Analysis (5 papers). Surachet Imlimthan is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (12 papers), Boron Compounds in Chemistry (5 papers) and Peptidase Inhibition and Analysis (5 papers). Surachet Imlimthan collaborates with scholars based in Finland, Germany and Switzerland. Surachet Imlimthan's co-authors include Anu J. Airaksinen, Mirkka Sarparanta, Hélder A. Santos, Mauri A. Kostiainen, Alexandra Correia, Outi Keinänen, Kalle Lintinen, Axel Rominger, Eleni Gourni and Euy Sung Moon and has published in prestigious journals such as Small, International Journal of Cancer and Molecules.

In The Last Decade

Surachet Imlimthan

20 papers receiving 318 citations

Peers

Countries citing papers authored by Surachet Imlimthan

Since Specialization

Citations

This map shows the geographic impact of Surachet Imlimthan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Surachet Imlimthan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Surachet Imlimthan more than expected).

Fields of papers citing papers by Surachet Imlimthan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Surachet Imlimthan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Surachet Imlimthan. The network helps show where Surachet Imlimthan may publish in the future.

Co-authorship network of co-authors of Surachet Imlimthan

This figure shows the co-authorship network connecting the top 25 collaborators of Surachet Imlimthan. A scholar is included among the top collaborators of Surachet Imlimthan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Surachet Imlimthan. Surachet Imlimthan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Biological evaluation of a glucose‐based boron carrier as a potential agent for boron neutron capture therapy 2025 ·International Journal of Cancer ·Surachet Imlimthan, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Heidi Liljenbäck, (unknown), Kristiina M. Huttunen, Anne Roivainen, Anu J. Airaksinen, Filip S. Ekholm, Outi Monni, Jarkko Rautio, Mirkka Sarparanta	1
2	Aluminum-[18F]fluoride radiolabeling of triarylphosphines for cell labeling via the perfluoroaryl azide Staudinger ligation 2025 ·EJNMMI Radiopharmacy and Chemistry ·(unknown), Surachet Imlimthan, Heidi Harjunpää, (unknown), (unknown), (unknown), Susanne Κ. Wiedmer, Filip S. Ekholm, Susanna C. Fagerholm, Mirkka Sarparanta	0
3	Development of new albumin-binding radiotracers for PET imaging of cerebrospinal fluid flow in the glymphatic system 2025 ·EJNMMI Radiopharmacy and Chemistry ·Mirva J Peltoniemi, Surachet Imlimthan, (unknown), (unknown), Terhi J. Lohela, Tuomas O. Lilius, Mirkka Sarparanta	0
4	Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2 2024 ·Molecules ·Tilman Läppchen, (unknown), (unknown), (unknown), Surachet Imlimthan, Euy Sung Moon, Ali Afshar‐Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni	6
5	Towards New Delivery Agents for Boron Neutron Capture Therapy: Synthesis and In Vitro Evaluation of a Set of Fluorinated Carbohydrate Derivatives 2024 ·Molecules ·(unknown), (unknown), (unknown), Surachet Imlimthan, Olli Aitio, Mirkka Sarparanta, Jarkko Rautio, Filip S. Ekholm	0
6	Translational assessment of a DATA-functionalized FAP inhibitor with facile 68Ga-labeling at room temperature 2023 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), Jens Kurth, Surachet Imlimthan, (unknown), (unknown), Euy Sung Moon, Tilman Läppchen, Hendrik Rathke, Sarah M. Schwarzenböck, Bernd J. Krause, Frank Rösch, Axel Rominger, Eleni Gourni	7
7	Development of [¹⁸F]AmBF₃ Tetrazine for Radiolabeling of Peptides: Preclinical Evaluation and PET Imaging of [¹⁸F]AmBF₃-PEG₇-Tyr³-Octreotide in an AR42J Pancreatic Carcinoma Model 2022 ·Bioconjugate Chemistry ·(unknown), (unknown), Surachet Imlimthan, (unknown), Helena E. Virtanen, Heidi Liljenbäck, Tuula Tolvanen, (unknown), Anne Roivainen, K. Helariutta, Mirkka Sarparanta, Anu J. Airaksinen	17
8	Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [⁸⁹Zr]Zr-DFO-PEG₅-Tz 2022 ·Bioconjugate Chemistry ·(unknown), Daniëlle J. Vugts, (unknown), Surachet Imlimthan, Mirkka Sarparanta, (unknown), (unknown), (unknown), Pauline A. Lang, Eero Hippeläinen, Wissam Beaino, Albert D. Windhorst, Anu J. Airaksinen	11
9	Synthesis and ex vivo biodistribution of two 68Ga-labeled tetrazine tracers: Comparison of pharmacokinetics 2022 ·Nuclear Medicine and Biology ·(unknown), (unknown), (unknown), Surachet Imlimthan, (unknown), Ana Isabel Fraguas‐Sánchez, Mirkka Sarparanta, R. Holland Cheng, Anu J. Airaksinen	7
10	Development of ⁶⁸Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET 2022 ·Molecular Pharmaceutics ·(unknown), Chun‐Chieh Chen, Mo Baikoghli, Surachet Imlimthan, (unknown), Mirkka Sarparanta, R. Holland Cheng, Anu J. Airaksinen	7
11	A Theranostic Cellulose Nanocrystal‐Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma 2021 ·Small ·Surachet Imlimthan, (unknown), Outi Keinänen, Wenzhong Zhang, Anu J. Airaksinen, Mauri A. Kostiainen, Brian M. Zeglis, Hélder A. Santos, Mirkka Sarparanta	38
12	New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress 2021 ·Pharmaceuticals ·Surachet Imlimthan, Euy Sung Moon, Hendrik Rathke, Ali Afshar‐Oromieh, Frank Rösch, Axel Rominger, Eleni Gourni	47
13	Evaluation of Organo [18F]Fluorosilicon Tetrazine as a Prosthetic Group for the Synthesis of PET Radiotracers 2020 ·Molecules ·(unknown), Surachet Imlimthan, Mirkka Sarparanta, K. Helariutta, Kristiina Wähälä, Anu J. Airaksinen	10
14	Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and In Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates 2020 ·Molecular Pharmaceutics ·(unknown), (unknown), (unknown), Surachet Imlimthan, Jan‐Erik Raitanen, (unknown), Hannu Maaheimo, Kristiina M. Huttunen, Sirpa Peräniemi, Anu J. Airaksinen, Mirkka Sarparanta, Mikael P. Johansson, Jarkko Rautio, Filip S. Ekholm	19
15	Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics 2020 ·European Journal of Pharmaceutics and Biopharmaceutics ·(unknown), Shiqi Wang, Ermei Mäkilä, Surachet Imlimthan, Mirkka Sarparanta, Alexandra Correia, (unknown), Jouni Hirvonen, Hélder A. Santos, Anu J. Airaksinen, (unknown), Jarno Salonen	16
16	Preparation and in vivo evaluation of red blood cell membrane coated porous silicon nanoparticles implanted with 155Tb 2020 ·Nuclear Medicine and Biology ·U. Jakobsson, Ermei Mäkilä, Antti Rahikkala, Surachet Imlimthan, (unknown), Sanjeev Ranjan, (unknown), Pasi Jalkanen, U. Köster, Kenichiro Mizohata, Hélder A. Santos, Jarno Salonen, Anu J. Airaksinen, Mirkka Sarparanta, K. Helariutta	13
17	Addressing the Biochemical Foundations of a Glucose-Based “Trojan Horse”-Strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to In Vitro Assessment 2020 ·Molecular Pharmaceutics ·(unknown), (unknown), (unknown), (unknown), Surachet Imlimthan, (unknown), Kristiina M. Huttunen, (unknown), Sirpa Peräniemi, Olli Aitio, Anu J. Airaksinen, Mirkka Sarparanta, Mikael P. Johansson, Jarkko Rautio, Filip S. Ekholm	24
18	Site-Specific 111In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model 2019 ·Pharmaceutics ·(unknown), (unknown), Surachet Imlimthan, (unknown), Mirkka Sarparanta, Wujun Xu, Vesa‐Pekka Lehto, Anu J. Airaksinen	13
19	Systematic in vitro biocompatibility studies of multimodal cellulose nanocrystal and lignin nanoparticles 2019 ·Journal of Biomedical Materials Research Part A ·Surachet Imlimthan, Alexandra Correia, Patrícia Figueiredo, Kalle Lintinen, Vimalkumar Balasubramanian, Anu J. Airaksinen, Mauri A. Kostiainen, Hélder A. Santos, Mirkka Sarparanta	38
20	Radiolabeled Molecular Imaging Probes for the In Vivo Evaluation of Cellulose Nanocrystals for Biomedical Applications 2018 ·Biomacromolecules ·Surachet Imlimthan, (unknown), Outi Keinänen, Alexandra Correia, Kalle Lintinen, Hélder A. Santos, Anu J. Airaksinen, Mauri A. Kostiainen, Mirkka Sarparanta	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact